Literature DB >> 27223621

Predictors of Clinical Outcome after Prostate Artery Embolization with Spherical and Nonspherical Polyvinyl Alcohol Particles in Patients with Benign Prostatic Hyperplasia.

Tiago Bilhim1, João Pisco1, José A Pereira1, Nuno Vasco Costa1, Lúcia Fernandes1, Luís Campos Pinheiro1, Marisa Duarte1, António G Oliveira1.   

Abstract

Purpose To assess predictors of outcome after prostate artery embolization (PAE) for benign prostatic hyperplasia with spherical particle polyvinyl alcohol (sPVA) and compare outcomes with the use of nonspherical particle polyvinyl alcohol (nsPVA). Materials and Methods This was a single-center retrospective institutional review board-approved study conducted from 2009 to 2015 in patients undergoing PAE with sPVA (n = 186; mean age ± standard deviation, 65.5 years ± 7.7) and nsPVA (n = 300; mean age, 65.3 years ± 7.6). The two cohorts were compared and analyzed for predictors of outcome with a Cox proportional hazards model and linear regression. Post-PAE prostate ischemia was measured with contrast material-enhanced magnetic resonance (MR) imaging in 23 patients with nsPVA and 25 patients with sPVA. The 24-hour post-PAE prostate-specific antigen (PSA) level was registered in 133 patients with sPVA. Prognostic values of MR imaging and PSA levels 24 hours after PAE were assessed with Cox and random-effects regressions. Results Predictors of clinical failure were older age (age over 65 years, P = .002), unilateral procedure (P = .002), and higher baseline International Prostate Symptom Score (IPSS, P = .033). Adjusted hazard ratio for clinical failure of sPVA was 1.273 (P = .16). Acute urinary retention was a predictor of lower IPSS after PAE (P = .002). The mean proportion of prostate ischemia was 11% with sPVA and 10% with nsPVA (P = .65). Lower IPSS after PAE was associated with a higher proportion of prostate ischemia (P = .009). Patients with a PSA level of at least 75 ng/mL (75 μg/L) 24 hours after PAE had a greater decrease in IPSS (P = .01). Prostate ischemic volume and PSA level 24 hours after PAE were correlated (Pearson r = 0.64, P = .014). Conclusion Clinical outcome was similar after PAE with sPVA and nsPVA. Younger age (up to 65 years), bilateral PAE, lower baseline IPSS, and acute urinary retention were predictors of better clinical outcome. The PSA level 24 hours after PAE correlated with prostate ischemia, and both correlated with clinical outcome. (©) RSNA, 2016.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27223621     DOI: 10.1148/radiol.2016152292

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  18 in total

Review 1.  State of the art of prostatic arterial embolization for benign prostatic hyperplasia.

Authors:  Mario Petrillo; Filippo Pesapane; Enrico Maria Fumarola; Ilaria Emili; Marzia Acquasanta; Francesca Patella; Salvatore Alessio Angileri; Umberto G Rossi; Igor Piacentini; Antonio Maria Granata; Anna Maria Ierardi; Gianpaolo Carrafiello
Journal:  Gland Surg       Date:  2018-04

Review 2.  Efficacy and safety of prostatic artery embolization for benign prostatic hyperplasia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Peng Xiang; Di Guan; Zhen Du; Yongxiu Hao; Wei Yan; Yonghui Wang; Yutong Liu; Dan Liu; Hao Ping
Journal:  Eur Radiol       Date:  2021-01-15       Impact factor: 5.315

3.  The value of contrast-enhanced ultrasonography in detection of prostatic infarction after prostatic artery embolization for the treatment of symptomatic benign prostatic hyperplasia.

Authors:  Hippocrates Moschouris; Konstantinos Stamatiou; Katerina Malagari; Kyriaki Marmaridou; Konstantinos Kladis-Kalentzis; Michail Kiltenis; Nikolaos Papadogeorgopoulos; Aikaterini Tsavari; Kassiani Manoloudaki
Journal:  Diagn Interv Radiol       Date:  2019-03       Impact factor: 2.630

4.  Prostate arterial chemoembolization for treatment of refractory hematuria and urinary retention in patients with localized advanced prostate cancer.

Authors:  Bing Yuan; Hainan Xin; Jin Xin Fu; Mao Qiang Wang; Jin Long Zhang; Feng Duan; Hui Yi Ye; Hong Kai Yu; Dui-Ping Feng; Kai Cheng; Xiu Jun Zhang
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-03-05       Impact factor: 5.554

5.  Long-Term Efficacy and Recurrence Prediction of Prostatic Artery Embolization for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

Authors:  Zhong-Wei Xu; Chun-Gao Zhou; Wei Tian; Hai-Bin Shi; Sheng Liu
Journal:  Cardiovasc Intervent Radiol       Date:  2022-09-21       Impact factor: 2.797

6.  MRI features after prostatic artery embolization for the treatment of medium- and large-volume benign hyperplasia.

Authors:  Hongtao Zhang; Yanguang Shen; Jingjing Pan; Haiyi Wang; Yan Zhong; Yingwei Wang; Huiyi Ye
Journal:  Radiol Med       Date:  2018-05-12       Impact factor: 3.469

7.  Effect of superselective prostatic artery embolization on benign prostatic hyperplasia.

Authors:  Yi Tang; Jian-Hui Zhang; Yao-Bin Zhu; Shao-Jie Wu; Sen-Lin Cai; Yan-Feng Zhou; Xin Qian; Jie-Wei Luo; Zhu-Ting Fang
Journal:  Abdom Radiol (NY)       Date:  2020-10-06

Review 8.  [Prostate artery embolization (PAE) : Technique and results].

Authors:  A Kovács
Journal:  Radiologe       Date:  2017-08       Impact factor: 0.635

Review 9.  Minimally Invasive Therapies for Benign Prostatic Obstruction: A Review of Currently Available Techniques Including Prostatic Artery Embolization, Water Vapor Thermal Therapy, Prostatic Urethral Lift, Temporary Implantable Nitinol Device and Aquablation.

Authors:  Tiago Bilhim; Patrick Betschart; Pavel Lyatoshinsky; Gautier Müllhaupt; Dominik Abt
Journal:  Cardiovasc Intervent Radiol       Date:  2022-01-18       Impact factor: 2.740

10.  Prostatic artery embolization: magnetic resonance image (MRI) findings in the early detection of prostate infarction in a canine spontaneous benign prostatic hyperplasia model.

Authors:  Vanesa Lucas-Cava; Francisco Miguel Sánchez-Margallo; Virginio García-Martínez; Carmen López-Sánchez; Claudia Báez-Díaz; Luis Dávila-Gómez; Juan Rafael Lima-Rodríguez; Fei Sun
Journal:  Transl Androl Urol       Date:  2021-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.